Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 adjuvant chemotherapy versus watchful waiting in high-risk locoregionally advanced nasopharyngeal carcinoma
ChiCTR1800017583Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Guangzhou Medical University
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Affiliated Cancer Hospital of Guangzhou Medical University. Primary endpoint: Progression-free survival. Started Sep 2018; status: recruiting.
02
Drugs
tegafur
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1800017583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017583.